Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noboru Yamamoto

Showing results (21-30 of 437) with videos related to

Pageof 44
Sort By:
Investigational New Drugs|February 3, 2017
Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experienceShinsuke Sasada, Nobuko Ushirozawa, Noriko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Current Status of Single-Agent Phase I Trials in Japan: Toward GlobalizationHidenori Mizugaki, Noboru Yamamoto, Yutaka Fujiwara, et al.
International Journal of Clinical Oncology|November 20, 2025
Pooled safety analysis of pimitespib for the treatment of patients with advanced gastrointestinal stromal tumorsYukinori Kurokawa, Noboru Yamamoto, Yuko Hirano, et al.
Japanese Journal of Clinical Oncology|February 6, 2010
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumorsKazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, et al.
Biomacromolecules|September 10, 2002
Chemical modification of chitosan. 14:(1) Synthesis of water-soluble chitosan derivatives by simple acetylationHitoshi Sashiwa, Norioki Kawasaki, Atsuyoshi Nakayama, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2005
Squaric monoamide monoester as a new class of reactive immunization hapten for catalytic antibodiesYang Xu, Noboru Yamamoto, Diana I Ruiz, et al.
Clinical Lung Cancer|September 6, 2011
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancerHajime Asahina, Ikuo Sekine, Hidehito Horinouchi, et al.
Investigational New Drugs|December 11, 2019
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumorsToshihiko Doi, Nobuaki Matsubara, Akira Kawai, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsYutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, et al.
Angewandte Chemie (International Ed. in English)|December 18, 2003
High-throughput screening by using a blue-fluorescent antibody sensorMasayuki Matsushita, Kazuhiro Yoshida, Noboru Yamamoto, et al.
Pageof 44

Showing results (21-30 of 437) with videos related to

Sort By:
Pageof 44
Investigational New Drugs|February 3, 2017
Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experienceShinsuke Sasada, Nobuko Ushirozawa, Noriko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Current Status of Single-Agent Phase I Trials in Japan: Toward GlobalizationHidenori Mizugaki, Noboru Yamamoto, Yutaka Fujiwara, et al.
International Journal of Clinical Oncology|November 20, 2025
Pooled safety analysis of pimitespib for the treatment of patients with advanced gastrointestinal stromal tumorsYukinori Kurokawa, Noboru Yamamoto, Yuko Hirano, et al.
Japanese Journal of Clinical Oncology|February 6, 2010
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumorsKazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, et al.
Biomacromolecules|September 10, 2002
Chemical modification of chitosan. 14:(1) Synthesis of water-soluble chitosan derivatives by simple acetylationHitoshi Sashiwa, Norioki Kawasaki, Atsuyoshi Nakayama, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2005
Squaric monoamide monoester as a new class of reactive immunization hapten for catalytic antibodiesYang Xu, Noboru Yamamoto, Diana I Ruiz, et al.
Clinical Lung Cancer|September 6, 2011
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancerHajime Asahina, Ikuo Sekine, Hidehito Horinouchi, et al.
Investigational New Drugs|December 11, 2019
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumorsToshihiko Doi, Nobuaki Matsubara, Akira Kawai, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsYutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, et al.
Angewandte Chemie (International Ed. in English)|December 18, 2003
High-throughput screening by using a blue-fluorescent antibody sensorMasayuki Matsushita, Kazuhiro Yoshida, Noboru Yamamoto, et al.
Pageof 44